ArticleJournal of the neurological sciences2012
Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study.
Article in Journal of the neurological sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Predictors of multiple sclerosis progression: A systematic review of conventional magnetic resonance imaging studies.PloS one · 2024Pooled it
- Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod.BMC neurology · 2016Trial
- Machine learning-optimized Combinatorial MRI scale (COMRISv2) correlates highly with cognitive and physical disability scales in Multiple Sclerosis patients.Frontiers in radiology · 2022Article
- Cortical and Subcortical Morphometric and Iron Changes in Relapsing-Remitting Multiple Sclerosis and Their Association with White Matter T2 Lesion Load : A 3-Tesla Magnetic Resonance Imaging Study.Clinical neuroradiology · 2019Article
- Diffusion tensor imaging and disability progression in multiple sclerosis: A 4-year follow-up study.Brain and behavior · 2019Article
- Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity.JAMA neurology · 2017Article
- The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis.Frontiers in neurology · 2017Review
- An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis.Journal of neurology · 2016Article
- The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis.Frontiers in neurology · 2016Article
- Novel composite MRI scale correlates highly with disability in multiple sclerosis patients.Multiple sclerosis and related disorders · 2015Article
- Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.Journal of neurology · 2015Article
- An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2.Neuroreport · 2014Article
- Brain Atrophy and Physical and Cognitive Disability in Multiple Sclerosis.Basic and clinical neuroscienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
Abstract
backgroundWe previously described a composite MRI scale combining T1-lesions, T2-lesions and whole brain atrophy in multiple sclerosis (MS): the magnetic resonance disease severity scale (MRDSS).
objectiveTest strength of the MRDSS vs. individual MRI measures for sensitivity to longitudinal change.
methodsWe studied 84 MS patients over a 3.2±0.3 year follow-up. Baseline and follow-up T2-lesion volume (T2LV), T1-hypointense lesion volume (T1LV), and brain parenchymal fraction (BPF) were measured. MRDSS was the combination of standardized T2LV, T1/T2 ratio and BPF.
resultsPatients had higher MRDSS at follow-up vs. baseline (p<0.001). BPF decreased (p<0.001), T1/T2 increased (p<0.001), and T2LV was unchanged (p>0.5). Change in MRDSS was larger than the change in MRI subcomponents. While MRDSS showed significant change in relapsing-remitting (RR) (p<0.001) and secondary progressive (SP) phenotypes (p<0.05), BPF and T1/T2 ratio changed only in RRMS (p<0.001). Longitudinal change in MRDSS was significantly different between RRMS and SPMS (p=0.0027); however, change in the individual MRI components did not differ. Evaluation with respect to predicting on-study clinical worsening as measured by EDSS revealed a significant association only for T2LV (p=0.038).
conclusionResults suggest improved sensitivity of MRDSS to longitudinal change vs. individual MRI measures. MRDSS has particularly high sensitivity in RRMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.